

NEUPATH HEALTH THE FIRST NORTH AMERICAN PROVIDER OF ARTHROSAMID[®], A REVOLUTIONARY INJECTION FOR KNEE OSTEOARTHRITIS

- Arthrosamid can provide pain relief for knee osteoarthritis patients for up to four years after a single procedure
- NeuPath continues to accelerate growth as it rolls out Arthrosamid across its clinic network
- Empowers NeuPath healthcare physicians to deliver innovative, best-in-class treatment to Canadians

TORONTO, ONTARIO, March 6, 2025 – NeuPath Health Inc. (TSXV:NPTH), (“NeuPath” or the “Company”), owner and operator of a network of clinics delivering category-leading chronic pain treatment, today announced that it has performed the first-ever injection of Arthrosamid in North America at its Mississauga, Ontario clinic. Prior to Health Canada’s approval of Arthrosamid, patients would travel to Europe to access this innovative hydrogel that has been shown to provide up to four years of pain relief for knee osteoarthritis sufferers.¹

“This is a major step forward in osteoarthritis options for Canadians,” said Joe Walewicz, NeuPath’s Chief Executive Officer. “It underscores our commitment to provide best chronic pain care to our patients as we scale up our clinic network and expand our services across Canada. We continue to seek out proven, innovative treatments that leverage our growing market presence and the skills of our healthcare professionals.”

Over four million Canadians live with osteoarthritis, with knee osteoarthritis being a leading cause of pain, mobility issues and reduced quality of life. The economic burden of arthritis in Canada was estimated to be \$6.4 billion, representing almost one third of the total cost of musculoskeletal diseases.² Worldwide, osteoarthritis is a leading cause of disability in older adults.³ Conventional non-surgical solutions like painkillers and corticosteroid injections provide only temporary relief. The addition of Arthrosamid enables the Company to reinforce its leadership in treatments for chronic pain as it expands its footprint across Canada.

About Arthrosamid

Arthrosamid (2.5% iPAAG) is a unique non-biodegradable hydrogel injection developed by Contura International A/S, a biotechnology company based in Denmark. Unlike traditional OA injections, Arthrosamid integrates into the synovial tissue of the knee, helping to cushion the joint and reduce pain with a single-dose. Conventional non-surgical solutions like painkillers and corticosteroid injections provide only temporary relief. Hydrogel-based injections have been administered more than 1.4 million times to patients worldwide.

About NeuPath

NeuPath operates a network of healthcare clinics and related businesses focused on improved access to care and outcomes for patients by leveraging best-in-class treatments and delivering patient-centered multidisciplinary care. We operate a network of medical clinics in Ontario and Alberta that provide comprehensive assessments and rehabilitation services to clients with chronic pain, musculoskeletal/back injuries, sports related injuries and concussions. In addition, NeuPath provides workplace health services and independent medical assessments to employers and disability insurers through a national network of healthcare providers, as well as contract research services to pharmaceutical and biotechnology companies. NeuPath is focused on enabling each individual to live their best life. For additional information, please visit www.neupath.com.

¹ Bliddal, H., et al. (2024) A Prospective Study of Polyacrylamide Hydrogel Injection for Knee Osteoarthritis: Results From 4 Years After Treatment. Presented at EORS 2024, Aalborg and Orthopaedic Proceedings of the Bone & Joint Journal.

² Life with arthritis in Canada: a personal and public health challenge, Government of Canada: canada.ca/en/public-health/services/chronic-diseases/arthritis/life-arthritis-canada-a-personal-public-health-challenge.html.

³ Hunter, David J et al. (2020) Osteoarthritis in 2020 and beyond: a Lancet Commission; The Lancet, Volume 396, Issue 10264, 1711 – 1712: [thelancet.com/journals/lancet/article/PIIS0140-6736\(20\)32230-3/fulltext](https://thelancet.com/journals/lancet/article/PIIS0140-6736(20)32230-3/fulltext)

Forward-Looking Statements

This news release contains forward-looking statements. All statements, other than statements of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future including, without limitation, the Company's expectation of rolling out the Arthrosamid procedure across its clinics in Canada are forward-looking statements. These forward-looking statements reflect the current expectations or beliefs of the Company based on information currently available to the Company. Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, the Company. Factors that could cause actual results or events to differ materially from current expectations included in this news release include, among other things, adverse market conditions, risks associated with obtaining and maintaining the necessary governmental permits and licenses related to the business of the Company, increasing competition in the market and other risks generally inherent in the chronic pain, sports medicine, concussion and workplace health services markets. A comprehensive discussion of these and other risks and uncertainties can be found in the Company's annual information form dated March 14, 2024 filed on SEDAR+ under the Company's profile at www.sedarplus.ca.

Any forward-looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or results or otherwise. Although the Company believes that the assumptions underlying the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and accordingly undue reliance should not be put on such statements due to their inherent uncertainty.

For more information, please contact:

Jeff Zygouras
Chief Financial Officer
info@neupath.com
(905) 858-1368

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS THE RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.